Objectives: To investigate PK of PEG-IFN Alpha in HCV infected patients using population modeling and to compare two software packages…
Read morePoster: Absorption and Physiology-Based PK
Whole Body Physiologically-Based Pharmacokinetic Model of Colistin and Colistimethate sodium in Critically Ill Patients
Objectives: Colistin is used as a salvage therapy for MDR GNB infections and administered as a prodrug, colistimethate sodium (CMS)….
Read moreApplication of a Physiologically Based Pharmacokinetic/Pharmacodynamic (PBPK/PD) Model to Investigate the Effect of OATP1B1 Genotypes on the Cholesterol Synthesis Inhibitory Effect of Rosuvastatin
Objectives: To develop a PBPK/PD model that links the hepato-cellular concentrations of rosuvastatin (RSTN), predicted by a permeability-limited liver model…
Read morePopulation PK Model for Pooled Data of Different Oral Diclofenac Formulations
Objectives: Diclofenac is available in different oral formulations, which are known to have considerable interindividual and intraindividual variation in their…
Read moreDevelopment of a population model to describe diurnal and chronokinetic variation in cilostazol pharmacokinetics
Objectives: Diurnal variation, characterized by higher Cmax and shorter Tmax after the morning dose in oral twice-a-day treatment, has been…
Read moreDevelopment of a PBPK model of doxorubicin
Objectives: The anthracycline antibiotic doxorubicin (DOX) is one of the most potent cytostatic agents and is used in both solid…
Read moreDevelopment of a detailed physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats
Objectives: The aim of the study is to develop a detailed physiologically based computational kidney model in order to simulate…
Read moreThe use of physiologically-based pharmacokinetic modeling in the design of pH-dependent target binding antibodies
Objectives: Reducing the binding affinity of therapeutic proteins to their target within acidic endosomal space is a strategy to increase…
Read morePharmacogenomics of Tamoxifen In Female Patients: A PBPK Model-based Investigation Including The Three Main Metabolites
Objectives: This work establishes a coupled physiologically-based pharmacokinetics (PBPK) model for tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen that is able to…
Read moreEvaluation of CYP2D6 Phenotype-Guided Tamoxifen Dosing in European Female Breast Cancer Patients using a PBPK-Model
Objectives: Tamoxifen is a first-line agent in the treatment of estrogen-receptor positive breast cancer [1]. Endoxifen is a secondary metabolite…
Read more